Iveric Bio Announces Proposed Offering of Common Stock

IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced that it is commencing an underwritten public offering of $250.0 million of shares of its common stock. In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock being offered. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares are to be offered by the Company.

Morgan Stanley, BofA Securities, Cowen and Stifel are acting as the book-running managers for the offering.

An automatically effective shelf registration statement on Form S-3 relating to the shares of common stock to be offered was filed with the Securities and Exchange Commission (the “SEC”) on October 21, 2021. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement related to the offering is being filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may also be obtained by contacting: Morgan Stanley, 180 Varick Street, 2^nd Floor, New York, NY 10014, Attn: Prospectus Department, by telephone: [phone], or by email at [e-mail]; BofA Securities, 200 North College Street, 3^rd floor, Charlotte, NC (28255-0001), Attn: Prospectus Department, by telephone: [phone], or by email at [e-mail]; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone: [phone], or by email at [e-mail]; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone: [phone], or by email at [e-mail].

This press release does not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.